223 related articles for article (PubMed ID: 18080693)
1. [Serum anti-p53 antibodies in gastric cancer patients].
Lawniczak M; Bielicki D; Sulzyc-Bielicka V; Marlicz K; Starzyńska T
Pol Merkur Lekarski; 2007 Sep; 23(135):192-5. PubMed ID: 18080693
[TBL] [Abstract][Full Text] [Related]
2. The detection of serum anti-p53 antibodies from patients with gastric carcinoma in China.
Qiu LL; Hua PY; Ye LL; Wang YC; Qiu T; Bao HZ; Wang L
Cancer Detect Prev; 2007; 31(1):45-9. PubMed ID: 17292563
[TBL] [Abstract][Full Text] [Related]
3. Serum antibodies against p53 in relation to cancer risk and prognosis in breast cancer: a population-based epidemiological study.
Lenner P; Wiklund F; Emdin SO; Arnerlöv C; Eklund C; Hallmans G; Zentgraf H; Dillner J
Br J Cancer; 1999 Feb; 79(5-6):927-32. PubMed ID: 10070892
[TBL] [Abstract][Full Text] [Related]
4. Clinical implications of serum anti-p53 antibodies for patients with gastric carcinoma.
Maehara Y; Kakeji Y; Watanabe A; Baba H; Kusumoto H; Kohnoe S; Sugimachi K
Cancer; 1999 Jan; 85(2):302-8. PubMed ID: 10023696
[TBL] [Abstract][Full Text] [Related]
5. Serum anti-p53 antibodies in gastric adenocarcinoma patients are associated with poor prognosis, lymph node metastasis and poorly differentiated nuclear grade.
Wu CW; Lin YY; Chen GD; Chi CW; Carbone DP; Chen JY
Br J Cancer; 1999 May; 80(3-4):483-8. PubMed ID: 10408857
[TBL] [Abstract][Full Text] [Related]
6. Circulating antibodies against p53 protein in patients with ovarian carcinoma. Correlation with clinicopathologic features and survival.
Angelopoulou K; Rosen B; Stratis M; Yu H; Solomou M; Diamandis EP
Cancer; 1996 Nov; 78(10):2146-52. PubMed ID: 8918407
[TBL] [Abstract][Full Text] [Related]
7. Association of positive serum anti-p53 antibodies with poor prognosis in bladder cancer patients.
Gumus E; Erdamar S; Demirel G; Horasanli K; Kendirci M; Miroglu C
Int J Urol; 2004 Dec; 11(12):1070-7. PubMed ID: 15663677
[TBL] [Abstract][Full Text] [Related]
8. Assessment of the prognostic relevance of serum anti-p53 antibodies in epithelial ovarian cancer.
Gadducci A; Ferdeghini M; Buttitta F; Cosio S; Fanucchi A; Annicchiarico C; Gagetti O; Bevilacqua G; Genazzani AR
Gynecol Oncol; 1999 Jan; 72(1):76-81. PubMed ID: 9889034
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of serum P53 antibody in patients with gastric cancer.
Shiota G; Ishida M; Noguchi N; Takano Y; Oyama K; Okubo M; Katayama S; Harada K; Hori K; Ashida K; Kishimoto Y; Hosoda A; Suou T; Ito H; Kawasaki H
Res Commun Mol Pathol Pharmacol; 1998 Jan; 99(1):41-51. PubMed ID: 9523354
[TBL] [Abstract][Full Text] [Related]
10. [Prevalence and prognostic value of serum anti-p53 antibodies in hepatocellular carcinoma. A study of 159 patients].
Sitruk V; Vaysse J; Chevret S; Ganne-Carrie N; Christidis C; Trinchet J; Beaugrand M
Gastroenterol Clin Biol; 2000 Dec; 24(12):1159-63. PubMed ID: 11173728
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of circulating anti-p53 antibodies in European patients with hepatocellular carcinoma.
Saffroy R; Lelong JC; Azoulay D; Salvucci M; Reynes M; Bismuth H; Debuire B; Lemoine A
Br J Cancer; 1999 Feb; 79(3-4):604-10. PubMed ID: 10027337
[TBL] [Abstract][Full Text] [Related]
12. Clinico-pathological characteristics of colorectal cancer and serum anti-p53 antibodies.
Bielicki D; Karbowniczek M; Sulzyc-Bielicka V; Kładny J; Boer C; Marlicz K; Domagała W
Pol J Pathol; 1999; 50(2):77-81. PubMed ID: 10481530
[TBL] [Abstract][Full Text] [Related]
13. [Prognostic significance of p53 autoantibodies in serum of patients with breast carcinoma].
Huober J; Sprenger H; Costa SD; Zentgraf H; Schmid H; Kaufmann M; Bastert G
Zentralbl Gynakol; 1996; 118(10):560-4. PubMed ID: 8999710
[TBL] [Abstract][Full Text] [Related]
14. Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer.
Goodell V; Salazar LG; Urban N; Drescher CW; Gray H; Swensen RE; McIntosh MW; Disis ML
J Clin Oncol; 2006 Feb; 24(5):762-8. PubMed ID: 16391298
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathologic significance in serum presence of anti-p53 antibody in patients with colorectal carcinoma.
Nozoe T; Yasuda M; Honda M; Inutsuka S; Korenaga D
Hepatogastroenterology; 2007; 54(77):1422-5. PubMed ID: 17708268
[TBL] [Abstract][Full Text] [Related]
16. Humoral p53 antibody response is a prognostic parameter in ovarian cancer.
Mayerhofer K; Tempfer C; Kucera E; Hefler L; Zeisler H; Kainz C; Zeillinger R; Sliutz G
Anticancer Res; 1999; 19(1B):875-8. PubMed ID: 10216509
[TBL] [Abstract][Full Text] [Related]
17. A new prognostic indicator for head and neck cancer--p53 serum antibodies?
Gottschlich S; Folz BJ; Goeroegh T; Lippert BM; Maass JD; Werner JA
Anticancer Res; 1999; 19(4A):2703-5. PubMed ID: 10470224
[TBL] [Abstract][Full Text] [Related]
18. Anti-p53 antibodies are rarely detected in serum of patients with rheumatoid arthritis and Sjögren's syndrome.
Mariette X; Sibilia J; Delaforge C; Bengoufa D; Brouet JC; Soussi T
J Rheumatol; 1999 Aug; 26(8):1672-5. PubMed ID: 10451060
[TBL] [Abstract][Full Text] [Related]
19. Preoperative serum antibodies against the p53 protein in patients with ovarian and endometrial cancer.
Gadducci A; Ferdeghini M; Buttitta F; Fanucchi A; Annicchiarico C; Prontera C; Bevilacqua G; Genazzani AR
Anticancer Res; 1996; 16(6B):3519-23. PubMed ID: 9042215
[TBL] [Abstract][Full Text] [Related]
20. Mutated p53 in tumors, mutant p53 and p53-specific antibodies in the circulation in patients with gastric cancer.
Maeta M; Saito H; Oka S; Tsujitani S; Ikeguchi M; Kaibara N
J Exp Clin Cancer Res; 2000 Dec; 19(4):489-95. PubMed ID: 11277328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]